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ABSTRACT
Objectives: To describe trends in the incidence and
prevalence of diabetic retinopathy (DR) in the UK by
diabetes type, age, sex, ethnicity, deprivation, region
and calendar year.
Design: Cohort study using the Clinical Practice
Research Datalink (CPRD).
Setting: UK primary care.
Participants: 7.7 million patients ≥12 contributing to
the CPRD from 2004 to 2014.
Primary and secondary outcome measures:
Age-standardised prevalence and incidence of diabetes,
DR and severe DR (requiring photocoagulation) by
calendar year and population subgroup. Relative risk of
developing DR and severe DR by population subgroup.
Results: The prevalence of DR was 48.4% in the
population type 1 diabetes mellitus (T1DM) (14 846/
30 657) and 28.3% (95 807/338 390) in the population
with type 2 diabetes mellitus (T2DM). Prevalence of
DR remained stable in people with T2DM and
decreased in people with T1DM. Screening for DR
increased over time for patients with T2DM and
remained static for patients with T1DM Incidence of
DR increased in parallel with the incidence of T2DM in
both diabetic populations. Among patients with T2DM,
relative risk of DR varied significantly by region, was
increased for older age groups and in men compared
with women, with risk of severe DR increased in South
Asian groups and more deprived groups. Relative risk
of DR for patients with T1DM varied by age and
region, but not by gender, ethnic group or deprivation.
Conclusions: This is the largest study to date
examining the burden of DR in the UK. Regional
disparities in incidence may relate to differences in
screening delivery and disease ascertainment. Evidence
that deprivation and ethnicity are associated with a higher
risk of severe DR highlights a significant potential health
inequality. Findings from this study will have implications
for professionals working in the diabetes and sight loss
sectors, particularly to inform approaches for diagnosis
of retinopathy and campaigning to better tackle the
disease for at risk groups.
INTRODUCTION
Diabetic retinopathy (DR) is the most
common form of eye disease among indivi-
duals with diabetes mellitus. In the UK,
within 20 years of diabetes diagnosis nearly
all people with type 1 and almost two-thirds
of people with type 2 diabetes (60%) have
some degree of retinopathy.1 2 DR is one of
the leading causes of visual impairment and
blindness in the UK, among people of
working age; compared with the general
population, risks of cataract and of glaucoma
are doubled among individuals with estab-
lished DR.3
DR is a progressive disease directly attribut-
able to diabetes, which affects the blood
vessels of the retina. The blood vessels can
Strengths and limitations of this study
▪ This study constitutes the largest ever sample
size to examine trends in the burden of diabetes
and diabetic retinopathy (DR) in the UK which
allowed for sufficient power to detect relation-
ships between population subgroups, which is
often unfeasible in smaller studies where popula-
tion sizes do not allow for such granular
comparisons.
▪ Since recording of screening of DR was incenti-
vised under Quality and Outcomes Framework
(QOF) from 2004 to 2014 and QOF indicators are
known to be well recorded by general practi-
tioners and so we anticipate that screening and
identification of DR will have been recorded with
a high degree of accuracy during the study
period.
▪ This study relied on coded diagnoses of diabetes
and retinopathy as we did not have access to
data from other sources such as retinal photog-
raphy or practitioner letters, which could have
been used to validate the diagnoses.
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leak, become blocked or proliferate excessively.4 5 If
untreated, this can lead to retinal damage and visual
impairment.6
Differences in the risk of diabetes by gender, ethnic
group and deprivation have been established in the UK
and worldwide.7–11 In the UK, the risk of developing
type 2 diabetes is elevated approximately twofold in
South Asian and African Caribbean communities com-
pared with the white British population.12–14 Ethnic dif-
ferences in diabetes are mirrored by ethnic differences
in DR in the UK and globally.15 16 In the USA, several
studies have reported differences between white, black,
Hispanic and Mexican American populations.17–20 For
example, the National Health and Nutrition
Examination Survey reported the prevalence of DR to
be 36% higher in black and 84% higher in Mexican
American populations relative to the white population
with diabetes.21 UK studies have demonstrated higher
prevalence of DR among individuals of South Asian eth-
nicity relative to white.16 22 Socioeconomic deprivation
has also been found to be associated with DR, with the
UK and international studies reporting higher preva-
lence among more deprived groups.23 24
In order to prevent, delay and better manage DR,
annual screening using digital photography is recom-
mended for all people with diabetes aged 12 and over in
the UK. Introduced in 2004, uptake of the screening
programme has increased steadily, achieving full
national coverage in 2008.25 Implementation of screen-
ing varies across each of the four devolved nations of the
UK; Typically, all people with diabetes aged 12 and over
are invited for a screening appointment via letter or
phone call, which can take place in general practices,
hospitals, at specialist diabetes clinics, mobile clinics or
at the high street opticians. Retinal photography to
assess grade of retinopathy is completed. If the DR is
considered to be sight threatening, the individual is
referred to hospital eye services for treatment, otherwise
the results are sent back to the general practitioner for
continuing diabetes care.26 27
Despite extensive literature detailing the prevalence
and incidence of diabetes in the UK, population-wide
measures of incidence and prevalence of DR in the UK
context have not been determined. Previous UK
focussed research on retinopathy has largely been
limited to estimates based on regional screening pro-
grammes or small general practices samples.28–32 Having
a more complete understanding of the burden of
disease due to DR across the diverse UK population will
help improve future service planning and provision of
preventive and therapeutic care. The aim of this study
was to generate nationally representative estimates of the
incidence and prevalence of DR in the UK between
2004 and 2014 using the Clinical Practice Research
Datalink (CPRD), and to examine trends in the preva-
lence and relative risk of retinopathy by diabetes type,
age, sex, ethnicity, socioeconomic deprivation and
region.
METHODS
Data sources
The CPRD is an electronic health database which cur-
rently contains longitudinal primary care records for
∼13.5 million patients from 601 general practices across
the UK (covering 7% of the UK population), of whom
5.5 million are currently active.33 The CPRD contains
anonymised patient-level information on demographics,
lifestyle data, clinical diagnoses, prescriptions and pre-
ventive care. The database was established in 1987, and
continuous observational data have been collected in
most practices for over 6 years yielding over 30 million
patient years of observation. Data undergo regular
quality checks and practices are deemed to be ‘up to
standard’ if their data are deemed to be of research-level
quality.33 The CPRD has been found to be representative
of the UK population with respect to gender, age and
ethnic group.33 34
Identification of DR
Within the CPRD, diagnoses and symptoms are coded
using the Read clinical hierarchy, which is the coding
standard used across the UK primary care.35 Clinical
terms to identify diagnoses of DR were agreed on via
consultation between the research team and clinicians.
All diagnoses of DR were identiﬁed by searching for
Read clinical terms in the CPRD. DR was classiﬁed as
severe if the codes pertained to laser therapy, advanced
retinopathy or proliferative retinopathy.
Onset of DR was deﬁned as the ﬁrst ever diagnostic
Read code entered onto the patient record. Patients
with a diagnosis for severe retinopathy at any time were
included in a subanalysis of patients with advanced
disease, with onset deﬁned as the earliest ever code of
severe DR on the patient record.
Screening for DR was identiﬁed using a set of clinical
terms which indicated that a screening event had
occurred. Codes indicating that an individual had been
invited to or referred for screening were not included. A
summary of the clinical terms used to identify DR and
screening can be found in the online supplementary
material table S1.
Identification of diabetes mellitus
For the purposes of this study, classiﬁcation of patients
into categories of type 1 diabetes or type 2 diabetes was
determined using algorithms developed by the UK
Biobank Study for use in electronic health records.36
The algorithms initially classify patients according to the
presence of diagnostic Read codes for type 1 or type 2
diabetes. The diagnoses are then conﬁrmed if support-
ing information such as prescriptions of antidiabetic
medications, raised blood glucose and diabetes process
of care measures are present. All individuals identiﬁed
as having type 1 or type 2 diabetes after successfully
passing through the adjudication algorithm were
included in the ﬁnal analysis.
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Covariate definition
Age was grouped into 10-year age bands. Deprivation
was classiﬁed using the Index of Multiple Deprivation
(IMD) and divided into quintiles.37 Each patient in the
study was assigned a deprivation score relating to the
deprivation value of their general practice. Information
on ethnic group was derived from the CPRD record
where available and updated using ethnicity recorded in
linked Hospital Episode Statistics data if missing in
CPRD. Conﬂicts between the two data sources were
resolved using a deﬁned and previously validated algo-
rithm.38 Ethnicity was grouped into the ﬁve categories of
the 2011 census, namely, white, South Asian, black
African/Caribbean, mixed and other. Patients with
missing ethnicity or with codes which were unusable
were collapsed into a category of unknown ethnicity (see
supplementary material for algorithm and Read codes
tables 4–5). Duration of diabetes at onset of DR
(expressed in years) was calculated by subtracting the
date of the ﬁrst diagnostic code for diabetes from the
date of the ﬁrst diagnostic code for DR. Age at diabetes
onset (expressed in years) was calculated by subtracting
the date of birth from the date of diabetes onset.
Statistical methods
A population-based cohort study was conducted to
examine the prevalence and incidence of DR in all
patients aged 12 years and over registered with the
CPRD between January 2004 and December 2014. The
prevalence and incidence of diabetes and DR and
severe DR was examined separately for individuals with
type 1 diabetes and type 2 diabetes. The
age-standardised prevalence of screening in each year
was also examined for individuals with type 1 and type 2
diabetes.
All prevalence and incidence estimates were standar-
dised against the mid-2014 UK population estimates
from the Ofﬁce for National Statistics.39 The overall
age-standardised prevalence of DR stratiﬁed by diabetes
status, gender, ethnic group, deprivation quintile and
region was calculated for the entire study population.
For the study of prevalence over time, the outcome was
deﬁned as all individuals with a relevant diagnostic code
at the midpoint of each calendar year from January
2004 to December 2014. Point prevalence was calculated
by dividing the number of individuals with DR, severe
DR by the number of patients in the CPRD aged
12 years and over on 1 July of each year. The proportion
of patients receiving DR screening in each year was
determined by dividing the number of patients with a
code for screening in each calendar year by the number
of patients in the CPRD as a whole, and with type 1 or
type 2 diabetes, aged 12 and over on 1 July of each year.
For the study of disease incidence, the outcome was
ﬁrst diagnosis of DR or severe DR between January 2004
and December 2014. Individuals with a ﬁrst diagnosis of
retinopathy prior to 2004 were excluded from the ana-
lysis. Incidence was calculated by dividing the number of
newly diagnosed patients aged 12 and over by the
number of person-years of follow-up of all eligible
patients aged 12 and over contributing to the CPRD for
each calendar year. Age standardised incidence rates of
DR and severe DR per 10 000 person-years of follow-up
time were calculated for all patients in the CPRD for
2014, the ﬁnal year of the study.
Cox proportional hazards regression was used to evalu-
ate the risk of DR in all patients between January 2004
and December 2014. HRs for the relative risk of DR and
severe DR, mutually adjusted for age, gender, depriv-
ation, ethnic group, region and duration of diabetes,
were calculated separately for individuals with type 1
and type 2 diabetes. The start of follow-up was deﬁned
as the latest of practice ‘up to standard date’ (up to
standard indicating the practice data meets the range of
quality criteria as deﬁned and applied by CPRD) or
12 months after the patients’ current registration date.
Follow-up time ended at the earliest date of; ﬁrst diagno-
sis of DR, transferring out of the practice, latest data col-
lection, death or 31 December 2014. Stata statistical
software V.13 was used for all analyses (StataCorp, Stata
Statistical Software: Release 13. 2013).
RESULTS
From the entire CPRD population of 13.7 million
patients, 7 707 475 patients registered with the CPRD
between 2004 and 2014, aged 12 and over were eligible
for inclusion in the study (see online supplementary
appendix ﬁgure 1). Among all patients aged 12 and
over, 338 390 patients with type 2 diabetes and 30 657
patients with type 1 diabetes were identiﬁed using the
diabetes classiﬁcation algorithms (see online supplementary
appendix ﬁgures 2–5 for full details).
Overall prevalence of DR
Over the 10-year study period, 79.3% of individuals with
type 1 diabetes and 82.6% of individuals with type 2 dia-
betes had evidence of ever having had a DR screen com-
pleted, with over 50% having had their latest screen in
the 15 months prior to the end of their follow-up
period.
A total of 144 362 prevalent cases of DR were identi-
ﬁed between 2004 and 2014, giving a crude 10-year
period prevalence of 1.9% in the entire CPRD popula-
tion, 48.4% in the population with type 1 diabetes and
28.3% in the population with type 2 diabetes. A total of
9085 prevalent cases of severe DR were identiﬁed during
the study period. The crude 10-year period prevalence
of severe DR was 0.1% in the CPRD population, 7.0% in
the population with type 1 diabetes and 1.4% in the
population with type 2 diabetes (table 1).
Mean duration of diabetes at time of DR onset ranged
from 6 years for people with type 2 diabetes to 15 years
for people with type 1 diabetes, with duration ∼5 years
longer for onset of severe DR.
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Age-standardised prevalence and incidence of DR
and screening over time
In the whole CPRD population, the age-standardised
prevalence of DR decreased over time from 2.6% to
2.2% while the age-standardised prevalence of severe
DR remained stable at 0.1%. The incidence of DR
increased from 12.1 events per 10 000 years in 2004
to a peak of 23.82 events per 10 000 person-years in
2011 before declining again (annual increase of 0.7
events per 10 000 person-years, p=0.062). The
incidence of severe DR remained stable at one event
per 10 000 person-years (no trend over time,
p=0.265).
The age-standardised proportion of patients having
received a DR screen in each calendar increased over
the 10-year study period for patients with type 2 diabetes
from 40.3% in 2004 to 63.9% in 2014 (annual increase
of 2.3%, p<0.001) and oscillated between 59 and 67%
for patients with type 1 diabetes over the study period
(no trend over time, p=0.291).
Among patients with type 2 diabetes, the prevalence
of DR reduced from 24.6% in 2004 to 23.1% in 2014.
Table 1 Demographic characteristics of the CPRD population registered between 2004 and 2014
All CPRD
patients
T1DM
patients
T2DM
patients
Population* N % N Per cent N Per cent
Total (12+) 7 707 475 100.0% 30 657 100.0% 338 390 100.0%
Gender
Men 3 790 664 49.2% 17 761 57.9% 187 141 55.3%
Women 3 916 811 50.8% 12 896 42.1% 151 249 44.7%
Ethnic group
White 4 006 927 52.0% 19 810 64.6% 205 168 60.6%
South Asian 223 090 2.9% 453 1.5% 15 840 4.7%
Black 142 070 1.8% 373 1.2% 7186 2.1%
Other 109 402 1.4% 254 0.8% 3891 1.2%
Mixed 50 363 0.7% 152 0.5% 1095 0.3%
Unknown 3 175 623 41.2% 9615 31.4% 105 210 31.1%
IMD quintile
1 (most affluent) 1 338 388 17.4% 5280 17.2% 52 280 15.5%
2 1 496 051 19.4% 5934 19.4% 61 008 18.0%
3 1 621 330 21.0% 6517 21.3% 71 982 21.3%
4 1 723 122 22.4% 6910 22.5% 79 130 23.4%
5 (least affluent) 1 470 726 19.1% 5833 19.0% 72 094 21.3%
Region
North east 121 334 1.6% 516 1.7% 5465 1.6%
North west 803 853 10.4% 3226 10.5% 40 255 11.9%
Yorkshire and the Humber 269 265 3.5% 1050 3.4% 10 888 3.2%
East midlands 296 884 3.9% 1182 3.9% 12 489 3.7%
West midlands 654 656 8.5% 2451 8.0% 30 710 9.1%
East of England 752 786 9.8% 3041 9.9% 29 139 8.6%
South west 651 327 8.5% 2601 8.5% 30 330 9.0%
South central 853 405 11.1% 3242 10.6% 33 416 9.9%
London 1 017 747 13.2% 3150 10.3% 39 281 11.6%
South east 792 775 10.3% 3123 10.2% 33 399 9.9%
Northern Ireland 199 509 2.6% 937 3.1% 9322 2.8%
Scotland 711 397 9.2% 3601 11.7% 31 387 9.3%
Wales 582 537 7.6% 2537 8.3% 32 309 9.5%
Retinopathy screen 2004–2014 710 445 8.7% 24 828 79.3% 279 495 82.6%
Retinopathy screen in last 15 months 336 960 4.1% 15 788 50.4% 180 268 53.3%
Diabetic retinopathy 144 362 1.9% 14 846 48.4% 95 807 28.3%
Severe diabetic retinopathy 9085 0.1% 2148 7.0% 4651 1.4%
Age at diabetes diagnosis
(in years, mean, SD)
26 (18) 60 (14)
Mean duration of diabetes at DR onset
(years, SD)
14.7 (12.2) 5.9 (6.9)
Mean duration of diabetes at severe DR
onset (years, SD)
20.9 (12.7) 10.4 (8.7)
*All columns refer to number and %, unless otherwise specified.
CPRD, Clinical Practice Research Datalink; DR, diabetic retinopathy; IMD, Index of Multiple Deprivation; T1DM, type 1 diabetes mellitus;
T2DM, type 2 diabetes mellitus.
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The age-standardised incidence of DR increased in par-
allel with the incidence of type 2 diabetes, increasing
from 113.2 events per 10 000 person-years in 2004 to
408.6 events per 10 000 person-years in 2011 and decli-
ning thereafter (annual increase of 26 events per 10 000
person-years, 95% CI13.2 to39.3, p=0.001). The
age-standardised prevalence of severe DRincreased from
0.3% in 2004 to 0.9% in 2014 (annual increase of 0.06%
per year, p<0.001). The age-standardised incidence of
severe DRincreased from 5.2 events per 10 000 person-
years in 2004 to 10.2 events per 10 000 person-years in
2014 (annual increase of 0.6 events per 10 000 person-
years, 95% CI0.01 to1.16, p=0.046) (ﬁgure 1).
Among patients with type 1 diabetes the age-
standardised prevalence of DR remained stable at 55%
(no trend over time p=0.917). The age-standardised inci-
dence of DR increased from 514.7 events per 10 000
person-years in 2004 to 832 events per 10 000 person-years
in 2009 and declined thereafter (annual increase of 55.6
events per 10 000 person-years from 2004 to 2009, 95% CI
29.6 to 81.7, p=0.004) The prevalence of severe DR
increased from 3.5% in 2004 to 8.0% in 2014 (annual
increase of 0.05%, 95% CI 0.04% to 0.05%, p<0.001). The
incidence of severe DR decreased non-signiﬁcantly from
48 events per 10 000 person-years in 2004 to 25.4 events
per 10 000 years in 2014 (no trend over time, p=0.459).
Age-standardised prevalence of DR in 2014
In 2014, the ﬁnal year of the study period, 73 658 preva-
lent cases of DR were identiﬁed, giving an age-
standardised point prevalence of 2.2% ( 95% CI 2.18%
to 2.21%) in the entire CPRD population, 54.8% ( 95%
CI 53.6% to 56.1%) in the population with type 1
diabetes and 22.7% ( 95% CI 22.0% to 23.8%) in the
population with type 2 diabetes (table 2).
Among patients with type 2 diabetes, the
age-standardised prevalence of DR was higher among
men and those of non-white ethnicity and varied sub-
stantially by geographic region. Age-standardised
prevalence of DR increased with age and with depri-
vation until quintile 4. The age-standardised preva-
lence of severe DR was higher for men and those of
South Asian and mixed ethnicity. Prevalence increased
with age and varied by geographic region, but not by
deprivation.
Among patients with type 1 diabetes, the prevalence
of DR and severe DR was comparable between men
and women and between deprivation quintiles.
Prevalence of DR was highest in the white ethnic
group compared with all other ethnic groups, while
prevalence of severe DR was highest in the black
group. Prevalence of DR and severe DR varied substan-
tially by geographic region.
Figure 1 Age-standardised prevalence and incidence of diabetes, screening and diabetic retinopathy 2004–2014. CPRD,
Clinical Practice Research Datalink; DR, diabetic retinopathy.
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Table 2 Age-standardised prevalence of diabetic retinopathy in the CPRD 2014
Diabetic retinopathy Severe diabetic retinopathy
T2DM population T1DM population T2DM population T1DM population
160 418 13 848 160 418 13 848
2014 denominator (12+) N % p Value N % p Value N % p Value N % p Value
Overall
Prevalence (95% CI) 49 166 22.7 (22.0–23.8) 7583 54.8 (53.6–56.1) 1933 0.9 (0.8–1.0) 1117 8.1 (7.6–8.6)
Gender
Men 28 299 23.5 <0.001 4393 54.5 0.916 1206 0.9 <0.001 638 7.9 0.546
Women 20 867 21.9 3190 55.3 727 0.8 479 8.4
Age group
12–34 246 14.3 <0.001 1522 32.9 <0.001 9 0.5 <0.001 125 2.7 <0.001
35–44 1307 20.4 1381 58.5 49 0.8 209 8.9
45–54 5039 24.2 1906 65.4 209 1 321 11.0
55–64 10 107 28.6 1376 70.8 437 1.2 222 11.4
65–74 14 837 32.1 888 70.4 620 1.3 162 12.9
75+ 17 630 35.3 5104 68.6 609 1.2 78 10.5
Ethnic group
White 30 253 23.6 <0.001 5028 55.3 <0.001 1105 0.8 <0.001 778 8.5 0.001
South Asian 2545 25.2 94 45.2 141 1.1 * 2.5
Black 1190 25.4 59 45.8 75 0.8 10 10.3
Other 605 29.3 47 46.8 21 0.8 * 4.4
Mixed 156 19.8 22 42.2 16 1.8 * 4.3
Unknown 14 417 20.8 2333 55.1 575 1.0 317 7.5
IMD quintile
1 (most affluent) 7354 20.3 <0.001 1501 55.1 0.010 276 1.0 0.435 226 8.4 0.114
2 9780 23.4 1558 54.8 430 0.8 244 8.6
3 9910 23.1 1541 55.9 340 0.8 218 7.7
4 12 144 25.9 1688 55.9 452 0.9 248 8.2
5 (least affluent) 9456 20.6 1233 51.8 398 0.9 174 7.6
Region
North east 580 26.9 <0.001 73 57.9 <0.001 16 0.7 <0.001 12 9.2 <0.001
North west 4846 19.8 677 49.1 175 0.9 102 7.5
Yorkshire and Humber 398 20.4 76 50.2 11 0.8 14 8.4
East midlands 218 44.4 17 68.1 * 0.6 6 24.4
West midlands 4310 22.1 555 55.0 177 0.8 94 9.4
East of England 2563 19.8 494 53.6 119 0.8 66 7.1
South west 4397 26.3 584 56.2 175 1.1 104 9.9
South central 5685 23.9 945 54.2 219 0.8 149 8.3
London 6427 23.8 709 50.3 290 0.9 96 7.0
South east 4635 17.4 773 49.4 157 0.6 103 6.5
Northern Ireland 813 10.6 240 39.7 77 0.7 37 627
Scotland 7930 31.9 1478 66.7 261 1.1 175 8.3
Wales 6634 23.2 962 58.9 254 1.1 159 9.7
*All figures standardised against the UK mid-2014 population, p values from χ2 test for unordered categorical variables, from test for trend for ordered categorical variables (age group and IMD
quintile). Table values under 5 are suppressed.
CPRD, Clinical Practice Research Datalink; IMD, Index of Multiple Deprivation; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus.
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Relative risk of retinopathy in patients with type 2
diabetes
Median follow-up time for patients with type 2 diabetes
was 9.1 years (IQR 5.4–10.9 years). Within this popula-
tion, fully adjusted HRs from Cox proportional hazards
regression showed that the risk of developing DRand
severe DRwas reduced in women compared withmen
(HR 0.93, 95% CI0.92 to0.95 for DR and HR 0.80, 95%
CI0.72 to0.89 for severe DR).
Relative to those aged 55–64, the risk of developing
DR was reduced in the youngest and oldest age groups.
In the analysis of severe DR, risk was increased in those
aged 35–44 and 45–54 relative to those aged 55–64 and
reduced in all older age groups.
Each 5-year increase in the duration of diabetes at
baseline was associated with a 17% increase in the risk
of DR ( 95% CI 1.16 to 1.18) and a 42% increase in the
risk of severe DR ( 95% CI 1.39 to 1.45) after adjustment
for all other factors.
Risk of DR was equivalent between ethnic groups in
the main analysis, and rose for the South Asian group
relative to the white group in the analysis of severe DR
(HR 1.25 95% CI 1.00 to 1.56).
No clear relationship between deprivation and retin-
opathy was clear in analysis of all DR. The risk severe
DR was raised in the second most afﬂuent group relative
to the most afﬂuent group only (HR 1.37 95% CI 1.16
to 1.63) (ﬁgure 2).
Risk of DR varied substantially by geographic region,
with differences attenuated for severe retinopathy. In
comparison to London (the reference region), risk of
retinopathy was reduced in Northern Ireland and the
east of England, and increased in most other regions of
the UK.
Relative risk of retinopathy in patients with type 1
diabetes
Median follow-up time for patients with type 1 diabetes
was 7.1 years (IQR 4.0–10.9 years). Within this popula-
tion, fully adjusted HRs from Cox proportional hazards
regression showed no evidence for differences in the
risk of developing DR or severe DR by gender, ethnic
group or deprivation.
Relative to those aged 55–64, the risk of developing
DR was reduced in the both older age groups. In the
analysis of severe DR, risk decreased as age increased.
Each 5-year increase in the duration of diabetes at
baseline was associated with a 10% increase in the risk
of DR ( 95% CI 1.09 to 1.11) and a 26% increase in the
risk of severe DR ( 95% CI 1.21 to 1.31) after adjustment
for all other factors. Regional differences in the risk of
retinopathy and severe retinopathy for patients with type
Figure 2 Relative risk of diabetic retinopathy in patients with type 2 diabetes by gender, ethnic group, age group, deprivation,
region and duration of diabetes. IMD, Index of Multiple Deprivation; T2DM, type 2 diabetes mellitus.
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1 diabetes mirrored those found in the analysis of
patients with type 2 diabetes (ﬁgure 3).
DISCUSSION
Main findings
The study has shown that while the age-standardised
prevalence of DR has remained stable over time for
patients with type 1 and type 2 diabetes, the prevalence
of severe DR has increased threefold over the 10-year
study period. In contrast, while the incidence of DR
among people with type 1 and type 2 diabetes has
increased to a peak and subsequently decreased, in par-
allel to the incidence of type 2 diabetes, the incidence
of severe DR has increased for patients with type 2 dia-
betes and halved for patients with type 1 diabetes. The
proportion of patients receiving a DR screen in each cal-
endar increased steadily over the 10-year study period
for patients with type 2 diabetes to 64% in 2014 and
remained stable over time for patients with type 2
diabetes.
The study has further demonstrated that, for indivi-
duals with type 2 diabetes, the relative risk of developing
DR varies by region, age group and gender, while the
relative risk of developing severe retinopathy varies also
by ethnicity.
The overall prevalence of DR found in our CPRD
population is comparable to that of contemporaneous
studies. A 2015 study of the National Diabetic
Retinopathy Screening Service for Wales reported the
prevalence of DR to be 56% for those with type 1 dia-
betes and 30.3% for those with type 2 diabetes.30 These
ﬁgures tally closely with the respective 10-year preva-
lence ﬁgures of 48.4% for patients with type 1 diabetes
and 28.3% for patients with type 2 diabetes from our
study overall, and also for the estimates speciﬁc to Wales
reported herein (58.9% and 23.2%, respectively).
Similarities extend to severe DR also; the same study
reports prevalences of 11.2% in those with type 1 dia-
betes and 2.9% in those with type 2 diabetes. Our study
has found the prevalence to be 10.3% and 2.4%,
respectively. A recent review of DR studies in western
countries has reported the prevalence of DR in to be
28.7% for all people with diabetes, further lending cre-
dence to our ﬁndings.40
The overall incidence of retinopathy increased to a
peak partway through the study before decreasing again.
Increases in the incidence of retinopathy are likely to be
related to increasing incidence of type 2 diabetes and
increased ascertainment of retinopathy through nation-
wide screening programmes, which increased in cover-
age over the duration of the study period. Annual
Figure 3 Relative risk of diabetic retinopathy in patients with type 1 diabetes by gender, ethnic group, age group, deprivation,
region and duration of diabetes. IMD, Index of Multiple Deprivation; T1DM, type 1 diabetes mellitus.
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incidence ﬁgures obtained in our study are largely in
line with incidence ﬁgures reported in the Liverpool
Diabetic Eye Study, which examined incidence among
patients with type 2 diabetes.31
A key ﬁnding of the study was large regional variations
in the relative incidence of retinopathy, after accounting
for age, gender, deprivation and ethnicity. Regional dif-
ferences in incidence may relate to regional differences
in the organisation and delivery of screening pro-
grammes, and subsequent ascertainment of disease. It
has been suggested that uptake of screening, and as a
result, opportunities for diagnosis, may be lower in rural
versus urban areas, due to decreased accessibility of
screening services.32 Qualitative research elucidating the
inﬂuence of practice-level factors on attendance at
screening has also identiﬁed challenges in identifying
DR including communication with screening services,
communication with patients, integration of screening
services with other aspects of clinical care and ethnically
diverse patient populations.26 41
The increased risk of severe DR for South Asian indivi-
duals with type 2 diabetes relative to the white group
mirrors ethnic differences in diabetes prevalence, and
may be due to the same underlying genetic and bio-
logical factors which predispose South Asian groups to
insulin resistance, as well as cultural factors such as
diet.42 43 Acculturation to western lifestyles among
migrants is also associated with an increase in risk of
developing non-communicable diseases, as migrant
populations shift towards more sedentary and urbanised
lifestyles.42 44 Similarly, increased risk of severe DR in
the more deprived quintiles relative to the least deprived
quintile is consistent with existing literature around
socioeconomic disparities in diabetes.32 45
Turning to patients with type 1 diabetes, the stability
of the prevalence of retinopathy was to be expected as
the prevalence and incidence of type 1 diabetes is not
subject to large increases resulting from an increasingly
obesogenic environment, as is the case with the current
epidemic of type 2 diabetes.
The differences in prevalence by gender and ethnic
group found here conﬁrm those of recent smaller UK
based studies. In 2012, Sivaprasad et al reported reduced
odds of prevalent retinopathy in women compared with
men (OR 0.93, 95% CI 0.90 to 0.97) and raised odds in
South Asian and blackAfrican/Caribbean groups com-
pared withwhite (South Asian OR 1.10, 95%CI 1.02
to1.18, blackOR 1.79, 95% CI1.70 to1.89) amongindivi-
duals with diabetes in the UK.46
Strengths
This study made use of high levels of ethnicity recording
and linkage with deprivation data provided by the Ofﬁce
for National Statistics (ONS) to describe patterns by eth-
nicity and IMD. This study constitutes the largest ever
sample size to examine trends in the burden of diabetes
and DR in the UK. This allowed for sufﬁcient power to
detect relationships between populations stratiﬁed by
gender, ethnic group, geographic region and depriv-
ation, which is often unfeasible in smaller studies where
population sizes do not allow for such granular compari-
sons. At the time of publication, this is the only national
study to examine ethnicity and deprivation in relation to
the prevalence and incidence of DR.
Since 2004 it has been a requirement of the UK
Quality and Outcomes Framework (QOF) that patients
with diabetes should be screened annually for DR, and
that screening should be recorded by general practi-
tioners in patient records. QOF indicators are known to
have been well recorded by general practitioners and so
we anticipate results of screening will have been
recorded with a high degree of accuracy during the
study period.47 48
The advantage of routine electronic health databases
is that they are regularly updated and can be used to
provide timely information on the demographic makeup
of the general population and on areas of growing
healthcare need.
The CPRD has been used extensively for observational
studies examining a wide range of health conditions and
the data held within have been widely validated.33 The
data in the CPRD are prospectively collected and, as a
result, the data are not subject to recall bias (the pres-
ence of a disease outcome affects the reporting of expos-
ure status) or observer bias (the knowledge of the
patient’s disease status inﬂuences ascertainment or
recording of exposure).
Limitations
The primary purpose of the clinical data held in the
CPRD is for patient care, rather than research. By its
nature it only includes information gathered at consult-
ation and is thus routinely collected rather than
researcher-led. As a result, the completeness and accur-
acy of data are subject to temporal changes in coding
practices, health priorities and population need.
Anything not reported to the general practitioner is
necessarily not recorded. The absence of a code does
not necessarily mean that an individual is free from that
condition, but could also be interpreted as being
unknown.
Information of ethnicity was missing for 30% of
patients with diabetes, which may have resulted in an
underestimate of the ethnic differences in incidence
and prevalence estimates of DR. In addition to incom-
plete data, a further potential problem with routine elec-
tronic health records is incorrect coding stemming from
errors in the way data is entered. A wide range of studies
have found the validity of diagnoses and process of care
measures in CPRD to be high.49–51 Combined with the
fact that the CPRD data are subject to ongoing internal
quality checks and that concerns with data quality are
fed back to the general practices, researchers can be
reassured that errors which do occur in the database are
kept to a minimum.
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This study relied solely on the coded diagnoses of dia-
betes, retinopathy, eye disease and visual impairment.
We did not have access to data from other sources such
as retinal photography or practitioner letters, which
could have been used to validate the diagnoses.
The use of multiple testing across a range of popula-
tion subgroups meant that some of the observed associa-
tions may have arisen due to chance.
Clinical trials have established duration of diabetes,
hyperglycaemia and hypertension as key risk factors in
the development of DR.52 53 Further work examining
the role of pharmacological treatment and risk factor
management will be essential in elucidating patterns of
DR further, particularly as the UK population ages and
the burden of diabetes grows.
Policy implications
According to the Ofﬁce for National Statistics, the size
of the UK population at the midpoint of 2014 was 64.6
million people.54 Given that the CPRD is representative
of the UK population structure, we estimate that the
absolute number of people with any form of DR in the
UK is ∼1.5 million and that the absolute number of
people with severe DR is around 140 000. Increases in
prevalence of DR are likely to be related to increasing
prevalence of type 2 diabetes mellitus and potentially
increased ascertainment through national screening
programmes.
Findings from the 2013 to 2014 screening pro-
grammes in England report highlighted the success of
DR screening programmes in reducing the burden of
DR in the UK, to the point where, it is now, no longer
the leading cause of blindness among working age
people in the UK.55 In 2014, attendance at DR screening
was removed from the QOF, meaning that this important
indicator will no longer be collected to such a high
accuracy for all diabetic patients. This will impact on
future research into retinopathy, and it is likely to have
serious negative implications on service planning for dia-
betic patients unless the indicator is reinstated. Whether
the proportion of patients receiving screening decreases
from the ﬁgures reported in this study after 2014, and
the impact this will have on future ascertainment and
management of DR will need to be explored.
Findings from this study will have implications for pro-
fessionals working in the diabetes and sight loss sectors,
particularly to inform approaches for diagnosis of retinop-
athy and campaigning to better tackle the disease for at
risk groups. Evidence that deprivation may be associated
with a higher risk of retinopathy, when viewed alongside
previous evidence of lower retinopathy screening uptake
among deprived groups, highlights a signiﬁcant potential
health inequality.56 The national diabetic retinopathy
screening programme and other stakeholders need to
target and improve access to screening and support
around self-management of diabetes for people living in
deprived areas to avoid increasing inequalities.
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